

ELEVATE EXCHANGE AND COLORADO OPTION

Formulary Updates to Elevate Exchange and Colorado Option Plans
 (Exchange Bronze HDHP/Standard,
 Exchange Silver Select/Standard,
 Exchange Gold Select/Standard,
 Colorado Option Bronze,
 Colorado Option Silver,
 Colorado Option Gold)

P&T/Formulary Committee Actions
 4Q2022 (Effective January 1, 2023)

Formulary Actions Effective: 01/01/2023															
Drug Attributes							Formulary Status		Utilization Management		Rationale of Changes				
							Marketplace (HIE)		HIE						
Category	Brand Name	Generic Name	Strength	Dosage Form	Route	Brand Status	Current Status	Action	Current Status	Action	COMMERCIAL	Committee Actions	Optional Benefit Exclusion	Optional Formulary Exclusion (HIE)	Client Communication - HIE
ASTHMA AND COPD	DURIXENT PEN	DUPILUMAB	300 MG/2ML	PEN INJECT	SUBCUTANE	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22			
ASTHMA AND COPD	DURIXENT PEN	DUPILUMAB	200MG/1.14	PEN INJECT	SUBCUTANE	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22			
ASTHMA AND COPD	DURIXENT SYRINGE	DUPILUMAB	300 MG/2ML	SYRINGE	SUBCUTANE	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22			
ASTHMA AND COPD	DURIXENT SYRINGE	DUPILUMAB	200MG/1.14	SYRINGE	SUBCUTANE	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22			
ASTHMA AND COPD	DURIXENT SYRINGE	DUPILUMAB	100MG/0.67	SYRINGE	SUBCUTANE	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22			
ASTHMA AND COPD	PROAIR HFA	ALBUTEROL SULFATE	90 MCG	HFA AER AD	INHALATION	MSB	3	S=3	NONE	A=ST	Low Net Cost Strategy	P&T 4Q22		Multi-Source Brand Exclusion	ST: TRIAL OF GENERIC ALBUTEROL SULFATE 90 MCG HFA INHALER IN THE PAST 120 DAYS
ASTHMA AND COPD	PROVENTIL HFA	ALBUTEROL SULFATE	90 MCG	HFA AER AD	INHALATION	MSB	3	S=3	NONE	A=ST	Low Net Cost Strategy	P&T 4Q22		Multi-Source Brand Exclusion	ST: TRIAL OF GENERIC ALBUTEROL SULFATE 90 MCG HFA INHALER IN THE PAST 120 DAYS
ASTHMA AND COPD	VENTOLIN HFA	ALBUTEROL SULFATE	90 MCG	HFA AER AD	INHALATION	MSB	3	S=3	NONE	A=ST	Low Net Cost Strategy	P&T 4Q22		Multi-Source Brand Exclusion	ST: TRIAL OF GENERIC ALBUTEROL SULFATE 90 MCG HFA INHALER IN THE PAST 120 DAYS
BEHAVIORAL HEALTH - OTHER	WAKIX	PITOLISANT HCL	4.45 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22			
BEHAVIORAL HEALTH - OTHER	WAKIX	PITOLISANT HCL	17.8 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22			
BEHAVIORAL HEALTH - OTHER	XYREM	SODIUM OXYBATE	500 MG/ML	SOLUTION	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22			
BEHAVIORAL HEALTH - OTHER	XYWAV	SODIUM CALCIUM MAG.POT OXYBATE	0.5G/ML	SOLUTION	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22			
CONTRACEPTION/OVOTOCICS	SLYND	DROSPIRENONE	4 MG (28)	TABLET	ORAL	SSB	3	S=3	QL ST	S=QL C=ST	Low Net Cost Strategy	P&T 4Q22			ST: TRIAL OF GENERIC NORETHINDRONE 0.35 MG TABLETS IN THE PAST 120 DAYS
DERMATOLOGY - ANTINFLAMMATORY	OPZELURA	RUXOLITINIB PHOSPHATE	1.5 %	CREAM (G)	TOPICAL	SSB	2	S=2	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22			
DIABETES	ADLYXIN	LIXISENATIDE	20 MCG/0.2	PEN INJECT	SUBCUTANE	SSB	3	S=3	QL ST	D=QL D=ST A=PA	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			
DIABETES	ADLYXIN	LIXISENATIDE	10-20 (1)	PEN INJECT	SUBCUTANE	SSB	3	S=3	QL ST	D=QL D=ST A=PA	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			
DIABETES	BYDUREON BCISE	EXENATIDE MICROSPHERES	2MG/0.85ML	AUTO INJECT	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	BYETTA	EXENATIDE	5MCG/0.02	PEN INJECT	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	BYETTA	EXENATIDE	10MCG/0.04	PEN INJECT	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	MOUNIARO	TIRZEPATIDE	10MG/0.5ML	PEN INJECT	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	MOUNIARO	TIRZEPATIDE	12.5MG/0.5	PEN INJECT	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	MOUNIARO	TIRZEPATIDE	15MG/0.5ML	PEN INJECT	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	MOUNIARO	TIRZEPATIDE	2.5 MG/0.5	PEN INJECT	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	MOUNIARO	TIRZEPATIDE	5 MG/0.5ML	PEN INJECT	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	MOUNIARO	TIRZEPATIDE	7.5 MG/0.5	PEN INJECT	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	OZEMPIC	SEMAGLUTIDE	0.25 OR .5	PEN INJECT	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	OZEMPIC	SEMAGLUTIDE	1/0.75 (3)	PEN INJECT	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	OZEMPIC	SEMAGLUTIDE	2MG/0.75ML	PEN INJECT	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	OZEMPIC	SEMAGLUTIDE	1MG/0.75ML	PEN INJECT	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	RYBELSUS	SEMAGLUTIDE	3 MG	TABLET	ORAL	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	RYBELSUS	SEMAGLUTIDE	7 MG	TABLET	ORAL	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	RYBELSUS	SEMAGLUTIDE	14 MG	TABLET	ORAL	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	TRULICITY	DULAGLUTIDE	0.75MG/0.5	PEN INJECT	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22			ST: TRIAL OF METFORMIN, SULFONYLUREA, PIOGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES

DIABETES	TRULICITY	DULAGLUTIDE	1.5 MG/D.5	PEN INICTR	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22		ST: TRIAL OF METFORMIN, SULFONYLUREA, PIAGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	TRULICITY	DULAGLUTIDE	4.5 MG/D.5	PEN INICTR	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22		ST: TRIAL OF METFORMIN, SULFONYLUREA, PIAGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	TRULICITY	DULAGLUTIDE	3 MG/D.5ML	PEN INICTR	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22		ST: TRIAL OF METFORMIN, SULFONYLUREA, PIAGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
DIABETES	VICTOZA 2-PAK	URAGLUTIDE	0.6 MG/D.1	PEN INICTR	SUBCUTANE	SSB	2	S=2	QL	A=ST S=QL	Clinical/Safety/Trade Relations Strategy	P&T 4Q22		ST: TRIAL OF METFORMIN, SULFONYLUREA, PIAGLITAZONE, OR COMBO PRODUCT CONTAINING ANY AFOREMENTIONED AGENTS AND DIAGNOSIS OF TYPE 2 DIABETES
HORMONAL DEFICIENCY	ELESTRIN	ESTRADIOL	0.87G	GEL MD PMP	TRANSDERM	SSB	3	S=3	QL ST	S=QL C=ST	Low Net Cost/Trade Relations Strategy	P&T 4Q22		ST: TRIAL OF GENERIC CLIMARA, MINIVELLE, VIVELLE-DOT OR DIVIGEL IN THE PAST 120 DAYS
HORMONAL DEFICIENCY	ESTROGEL	ESTRADIOL	1.25 G	GEL MD PMP	TRANSDERM	SSB	3	S=3	NONE	A=ST	Low Net Cost/Trade Relations Strategy	P&T 4Q22		ST: TRIAL OF GENERIC CLIMARA, MINIVELLE, VIVELLE-DOT OR DIVIGEL IN THE PAST 120 DAYS
HORMONAL DEFICIENCY	EVAMIST	ESTRADIOL	1.53/SPRAY	SPRAY	TRANSDERM	SSB	3	S=3	QL ST	S=QL C=ST	Low Net Cost/Trade Relations Strategy	P&T 4Q22		ST: TRIAL OF GENERIC CLIMARA, MINIVELLE, VIVELLE-DOT OR DIVIGEL IN THE PAST 120 DAYS
INFLAMMATORY DISEASE	DUROLANE	HYALURONATE SODIUM, STABILIZED	60 MG/3 ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Aug. FBRC		
INFLAMMATORY DISEASE	EUFLEXIA GEL-ONE, GENVISC 850, HYALGAN, SODIUM HYALURONATE, SUPARTZ EX, SYNJOINT, TRIBLURON, TRIVISC, VISCO-3	HYALURONATE SODIUM	20 MG/2 ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Aug. FBRC		
INFLAMMATORY DISEASE	GELSYN-3	HYALURONATE SODIUM	16.8MG/2ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Aug. FBRC		
INFLAMMATORY DISEASE	HYALGAN	HYALURONATE SODIUM	10 MG/ML	VIAL	INTRAARTIC	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Aug. FBRC		
INFLAMMATORY DISEASE	HYMOVIS	HYALURONATE, MOD. NON-CROSSLINK	24 MG/3 ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Aug. FBRC		
INFLAMMATORY DISEASE	MILLIPRED	PREDNISOLONE	5 MG	TABLET	ORAL	SSB	2	S=2	NONE	A=ST	Low Net Cost Strategy	P&T 4Q22		ST: TRIAL OF 2 OF THE FOLLOWING: GENERIC PREDNISONE TABS, GENERIC METHYLPREDNISOLONE TABS OR PREDNISOLONE 15MG/5ML ORAL SOLN IN THE PAST 365 DAYS
INFLAMMATORY DISEASE	MONOVISC	HYALURONATE SODIUM, STABILIZED	88 MG/4 ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Aug. FBRC		
INFLAMMATORY DISEASE	ORTHOVISC	HYALURONATE SODIUM	30 MG/2 ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Aug. FBRC		
INFLAMMATORY DISEASE	PENCILLAMINE	PENCILLAMINE	250 MG	CAPSULE	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
INFLAMMATORY DISEASE	PENCILLAMINE	PENCILLAMINE	250 MG	TABLET	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
INFLAMMATORY DISEASE	SYNVISC	HYLAN G-F 20	16MG/2ML	SYRINGE	INTRAARTIC	SSB	3	C=2	PA	C=PA	Trade Relations Strategy	Aug. FBRC		
INFLAMMATORY DISEASE	SYNVISC ONE	HYLAN G-F 20	48 MG/6 ML	SYRINGE	INTRAARTIC	SSB	3	C=2	PA	C=PA	Trade Relations Strategy	Aug. FBRC		
LOWER GASTROINTESTINAL DISORDERS - BOWEL INFLAMMAT	DIPENTUM	OLSALAZINE SODIUM	250 MG	CAPSULE	ORAL	SSB	3	S=3	ST	C=ST	Low Net Cost/Trade Relations Strategy	Ad-Hoc Formulary Maintenance		ST: TRIAL OF LIALDA IN THE PAST 120 DAYS
LOWER GASTROINTESTINAL DISORDERS - BOWEL INFLAMMAT	MESALAMINE DR	MESALAMINE	400 MG	CAP(DRTAB)	ORAL	GENERIC	1	S=1	ST	D=ST	Low Net Cost/Trade Relations Strategy	Ad-Hoc Formulary Maintenance		
LOWER GASTROINTESTINAL DISORDERS - OTHER	PHEBURANE	SODIUM PHENYLBUTYRATE	483 MG/G	GRANULES	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
NEOPLASTIC DISEASE	ERLEADA	APALUTAMIDE	60 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
NEOPLASTIC DISEASE	NUBEQA	DAROLUTAMIDE	300 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
NEOPLASTIC DISEASE	PEMAZYRE	PEMIGATINIB	4.5 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
NEOPLASTIC DISEASE	PEMAZYRE	PEMIGATINIB	9 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
NEOPLASTIC DISEASE	PEMAZYRE	PEMIGATINIB	13.5 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
NEOPLASTIC DISEASE	TRUSELTIQ	INFIGRATINIB PHOSPHATE	50 MG/DAY	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
NEOPLASTIC DISEASE	TRUSELTIQ	INFIGRATINIB PHOSPHATE	75 MG/DAY	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
NEOPLASTIC DISEASE	TRUSELTIQ	INFIGRATINIB PHOSPHATE	100 MG/DAY	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
NEOPLASTIC DISEASE	TRUSELTIQ	INFIGRATINIB PHOSPHATE	125 MG/DAY	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
NEOPLASTIC DISEASE	XATMEP	METHOTREXATE	2.5 MG/ML	SOLUTION	ORAL	SSB	4	C=3	QL ST	S=QL S=ST	Clinical/Safety Strategy	Ad-Hoc Formulary Maintenance		
NEOPLASTIC DISEASE	XTANDI	ENZALUTAMIDE	40 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
NEOPLASTIC DISEASE	XTANDI	ENZALUTAMIDE	40 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
NEOPLASTIC DISEASE	XTANDI	ENZALUTAMIDE	80 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
NEUROLOGICAL DISEASE - MISCELLANEOUS	TASCENSO ODT	FINGOLIMOD LAURYL SULFATE	0.25 MG	TAB RAPDS	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	P&T 4Q22		
OTHER DRUGS	TRIENTINE HCL	TRIENTINE HCL	250 MG	CAPSULE	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
OTHER RESPIRATORY DISORDERS	ESBRIET	PIRPHENDIONE	267 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 4Q22		
VAGINAL DISORDERS	CLINDESSE	CLINDAMYCIN PHOSPHATE	2 %	CRM ER (G)	VAGINAL	SSB	3	S=3	NONE	A=ST	Low Net Cost Strategy	P&T 4Q22		ST: TRIAL OF GENERIC CLINDAMYCIN VAGINAL CREAM IN THE PAST 120 DAYS

MedImpact Managed Formulary Actions				
RATIONALE OF CHANGES				
Trade Relations Strategy				
Approach based on a financial review to deliver low net cost opportunities through pharmaceutical manufacture agreement strategies while taking into consideration the expected market share shift, future pipeline products, member impact and plan impact.				
Low Net Cost Strategy				
Delivering cost-efficient and clinically appropriate formulary content to meet the pharmacy benefit management needs of MedImpact clients; including appropriate development of preferred drug lists with consideration of low net cost strategies that includes MAC lists, non-pharmaceutical manufacture agreement strategies, and other cost management tools.				
Clinical/Safety Strategy				
Delivering cost-efficient and clinically appropriate formulary content to promote member safety and savings through the evaluation of scientific evidence, standards of practice, peer-reviewed medical literature, clinical practice guidelines, and guidance from the U.S. Food and Drug Administration (FDA)/Center for Disease Control (CDC).				
Regulatory Update				
Formulary/utilization management changes to comply with federal and/or state statutes, regulations, rules and policy requirements that pertain to the administration of the pharmacy benefit.				
LEGEND				
Note: The drug names listed are for reference purposes and denote action on the chemical entity unless otherwise specified. Where generic and brand products for a chemical entity co-exist, coverage and copayment for each will be a function of plan benefit design.				
FORMULARY		UTILIZATION MANAGEMENT (UM)		OPTIONAL BENEFIT EXCLUSION
Formulary Status	Formulary Actions	UM Definition	UM Actions	Coverage for each category will be a function of plan benefit design. These products may be excluded on client benefits. Formulary and UM decisions only apply for clients who choose to provide coverage for these drug categories.
F = Formulary	C = Change	AGE = Age restriction	A = Add UM	Antiobesity
NF = Non-Formulary	S = Sustain	QL = Quantity Limit	D = Delete UM	Cosmetic Indications
E = Excluded		ST = Step Therapy	C = Change UM	Dietary Supplements and Non-Drug Products
NC = Not covered		PA = Prior Authorization	E = Excluded drug from formulary	Drugs to Treat Impotency or Sexual Dysfunction
PGF = Perpetual Grandfathering		HST= Hard Step (Step without grandfathering-member must try preferred agents)	S = Sustain UM	Infertility
S = Specialty				Medical Foods: Dietary supplements, Enteral Feeding,
				Non-Self Administered Drug (NSA)
				Ostomy Supplies
				Class O = Over the Counter Products
				Class Q = Products that are neither drugs nor devices, such as dietary supplements (including prenatal and other vitamins), medical foods, herbal preparations, and bulk flavorings or colorants
				Diagnostics